A male in his 50s presented with profound leucocytosis, systemic symptoms and marked hepatosplenomegaly. Initial workup with peripheral blood flow cytometry suggested T-cell prolymphocytic leukaemia ...

August 19, 2011 — The US Food and Drug Administration has granted accelerated approval of brentuximab vedotin infusion (Adcetris, Seattle Genetics, Inc) for the treatment of relapsed or refractory ...

Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell and T-cell ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

Brentuximab vedotin is currently funded only for people whose lymphoma has returned or has not responded to earlier treatment. Using brentuximab vedotin earlier is expected to support better outcomes ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of ...

Implant rupture must be ruled out in the presence of a large fluid effusion surrounding the implant. Effusions that develop within 1 year of surgery may indicate a postsurgical hematoma or effusion, ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell and T-cell ...